Evaluation Of Safety Of Azilsartan And Olmesartan In Patients Of Hypertension: Randomized Controlled Trial.

: Background: Renin‐angiotensin aldosterone system (RAAS) inhibitor either angiotensin‐converting enzyme inhibitor or an angiotensin II receptor blocker (ARB) plus diuretic is a widely used for treatment of hypertension. Objective: To evaluate safety of azilsartan and olmesartan in patients of hypertension. Material and methods: A randomized, prospective, open label, comparative study was carried out in Pharmacology and Medicine department at Dr. R.P.G.M.C. Kangra at Tanda, HP. The study stretched over one year and haemoglobin (Hb), renal function test (RFT), liver function test (LFT), serum electrolytes were monitored at first, third and sixth month. Out of 69 patients, 35 patients in group A were prescribed tablet azilsartan 40 mg/day and 34 patients in group B were prescribed tablet olmesartan 20 mg/day along with chlorthalidone 12.5 mg/day in both the groups. Statistical analysis: Data was presented as mean + SD. Student’s t-test was used for comparing continuous variables between the two groups. P value < 0.05 was considered significant Results: Both the groups had normal range of haemoglobin, renal function test , liver function test and serum electrolyte over 6 months of period. There was no hepatotoxicity, nephrotoxicity, electrolyte imbalance and haematological toxicity observed in patients. Conclusion: Azilsartan and olmesartan were safe in patients of hypertension.

• Publication year

  2023

• Venue

  International journal for research trends and innovation

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.56975/ijrti.v8i6.187389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Olmesartan.

  2017cited by this paper
• Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence

  2013cited by this paper
• Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.

  2011cited by this paper
• The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure

  2011cited by this paper
• Combination therapy in hypertension

  2007cited by this paper
• Medical Sciences

  1983cited by this paper

• No citing papers are available for this paper.